FDA grants orphan drug designation to TST001 for gastric cancer

FDA grants orphan drug designation to TST001 for gastric cancer

The FDA granted orphan drug designation to TST001 for treatment of gastric and gastroesophageal junction cancers, according to the agent’s manufacturer.An estimated 120,300 people in the United States have gastric cancer, according to SEER data. Gastric cancers that express Claudin18.2 typically are treated with surgical resection, chemotherapy or immunotherapy.TST001 (Transcenta Holding Limited) is an anti-Claudin18.2 monoclonal antibody.Preclinical and clinical data showed TST001 had potent anti-tumor activity in tumor models of gastric cancer and patients with gastric cancer whoRead More

Share on facebook
Share on twitter
Share on linkedin